QT Prolongation Alone Does Not Assess Arrhythmic Potential - FDA's Lipicky
Executive Summary
Cardiac QT interval prolongation alone is not a sufficient measure of a drug's potential to cause arrhythmic disturbances, FDA Division of Cardio-Renal Drug Products Director Raymond Lipicky, MD, suggested.